NASDAQ$XNCR
Xencor Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2024.
Xencor reported a net loss of $68.0 million, or $(1.11) per share, for the first quarter ended March 31, 2024. Revenues for the quarter were $12.8 million, compared to $19.0 million for the same period in 2023. Cash, cash equivalents and marketable debt securities totaled $646.7 million as of March 31, 2024.
- First patient dosed in Phase 1 study of XmAb®541 (CLDN6 x CD3) for CLDN6-positive tumors.
- FDA approved Ultomiris® (Alexion Pharmaceuticals, Inc.) for adults with NMOSD.
- Single dose of investigational antibody with Xtend™ confers protection against malaria infection.
- Bart Cornelissen was appointed as Xencor’s senior vice president and chief financial officer.
Headline financials
Revenue & EPS history
Xencor · Revenue · Quarterly
$12.8M
Forward guidance
Xencor expects to end 2024 with between $475 million and $525 million in cash, cash equivalents and marketable debt securities, and to have cash to fund research and development programs and operations into 2027.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
-0.1%
Avg return
Earnings day
-1.1%
Avg return
5 days after
-0.1%
Avg return
30 days after
48%
25 / 52 earnings
Positive
+11.3%
Q2 2018
Best reaction
-16.6%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.2% | -0.5% | -8.4% | |
| Q4 2025 | +1.5% | +4.1% | -3.3% | |
| Q3 2025 | -2.4% | +3.5% | +20.4% | |
| Q1 2025 | +0.2% | -4.6% | +12.3% | |
| Q3 2024 | +7.7% | +8.3% | +17.8% | |
| Q2 2024 | -6.9% | -16.4% | -13.3% | |
| Q1 2024 | -5.0% | -13.9% | -8.1% | |
| Q4 2023 | -11.9% | -7.9% | -14.5% | |
| Q3 2023 | -6.3% | -7.3% | +9.8% | |
| Q2 2023 | +2.8% | +1.4% | -4.6% | |
| Q1 2023 | -2.2% | -2.4% | -1.6% | |
| Q4 2022 | -3.2% | -6.1% | -18.3% | |
| Q3 2022 | +8.6% | +9.0% | +9.9% | |
| Q2 2022 | +2.3% | +1.4% | -8.5% | |
| Q1 2022 | -1.0% | -2.5% | -16.7% | |
| Q4 2021 | +1.3% | -2.4% | -12.3% | |
| Q3 2021 | -7.0% | -6.4% | -13.3% | |
| Q2 2021 | +2.9% | -2.3% | +7.8% | |
| Q1 2021 | -2.4% | -6.3% | -10.4% | |
| Q4 2020 | -1.3% | +0.3% | -10.8% | |
| Q3 2020 | -8.7% | -3.9% | -5.7% | |
| Q2 2020 | -3.2% | +1.0% | +6.6% | |
| Q1 2020 | +7.1% | +7.3% | -3.2% | |
| Q4 2019 | -8.8% | -7.6% | -18.2% | |
| Q3 2019 | -1.0% | -1.0% | +20.9% | |
| Q2 2019 | -16.6% | -15.6% | -18.9% | |
| Q1 2019 | +10.7% | +4.9% | -3.5% | |
| Q4 2018 | -3.1% | -0.8% | +1.3% | |
| Q3 2018 | +6.2% | -0.3% | +3.7% | |
| Q2 2018 | +11.3% | +10.0% | +10.1% | |
| Q1 2018 | -2.5% | +4.4% | +38.4% | |
| Q4 2017 | +4.8% | +0.9% | +2.6% | |
| Q3 2017 | +2.1% | +4.6% | +10.7% | |
| Q2 2017 | +4.7% | -3.9% | -1.9% | |
| Q1 2017 | -6.8% | -6.3% | -12.0% | |
| Q4 2016 | +7.6% | +5.5% | -5.6% | |
| Q3 2016 | -11.0% | -4.7% | +24.9% | |
| Q2 2016 | +9.4% | +16.0% | +10.7% | |
| Q1 2016 | -2.9% | — | — | |
| Q4 2015 | +11.2% | — | — | |
| Q3 2015 | +4.6% | — | — | |
| Q2 2015 | -2.2% | — | — | |
| Q1 2015 | -5.5% | — | — | |
| Q4 2012 | +1.8% | — | — | |
| Q4 2014 | -0.9% | — | — | |
| Q3 2014 | +3.6% | — | — | |
| Q3 2013 | +3.6% | — | — | |
| Q2 2013 | +1.7% | — | — | |
| Q2 2014 | +2.6% | — | — | |
| Q4 2013 | -1.6% | — | — | |
| Q1 2013 | -1.6% | — | — | |
| Q1 2014 | -2.3% | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro